Climb Bio's Budoprutug Receives FDA Fast Track Designation for Primary Membranous Nephropathy Treatment.

Climb Bio announced FDA Fast Track Designation for budoprutug, an anti-CD19 monoclonal antibody, for the treatment of primary membranous nephropathy (pMN). The designation recognizes the urgent need for new therapies in pMN and supports the acceleration of budoprutug development efforts. The drug demonstrated complete peripheral B-cell depletion, serologic remission, and clinical remission in a completed Phase 1b study, with a favorable safety profile. Climb Bio anticipates sharing initial data from the ongoing Phase 2 study in the second half of 2026.